Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Applied NeuroSolutions
Biomarker may predict Alzheimer disease progression
June 22nd, 2005
A biomarker pioneered by Applied NeuroSolutions (APNS) and exclusively utilized in its Alzheimer diagnostic assay, shows great promise in predicting brain atrophy in patients with Alzheimer disease, according to a group of researchers in the U.S., Canada, and Europe led by Harald Hampel and published recently in the Archives of Neurology. According to John DeBernardis, president and CEO of Applied NeuroSolutions and a coauthor of the study, "Finding a biomarker that effectively predicts who will get Alzheimer's disease has been considered the Holy Grail of Alzheimer's research for many years. "We now believe that variations in the levels of...
Source: Physician Law Weekly (2005-06-22)
|
